Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 451 entries
Sorted by: Best Match Show Resources per page
Acute kidney injury in neonatal intensive care: Medicines involved.

The International journal of risk & safety in medicine

Safina AI, Daminova MA, Abdullina GA.
PMID: 26639729
Int J Risk Saf Med. 2015;27:S9-S10. doi: 10.3233/JRS-150669.

BACKGROUND: The incidence of acute kidney injury (AKI) in neonates in the intensive care units and neonatal intensive care (NICU) according Plotz et al. ranges from 8% to 22% [3]. According to Andreoli, neonatal death due to AKI in...

Cite
Safina AI, Daminova MA, Abdullina GA. Acute kidney injury in neonatal intensive care: Medicines involved. Int J Risk Saf Med. 2015;27:S9-S10doi: 10.3233/JRS-150669.
Safina, A. I., Daminova, M. A., & Abdullina, G. A. (2015). Acute kidney injury in neonatal intensive care: Medicines involved. The International journal of risk & safety in medicine, 27S9-S10. https://doi.org/10.3233/JRS-150669
Safina, A I, et al. "Acute kidney injury in neonatal intensive care: Medicines involved." The International journal of risk & safety in medicine vol. 27 (2015): S9-S10. doi: https://doi.org/10.3233/JRS-150669
Safina AI, Daminova MA, Abdullina GA. Acute kidney injury in neonatal intensive care: Medicines involved. Int J Risk Saf Med. 2015;27:S9-S10. doi: 10.3233/JRS-150669. PMID: 26639729.
Copy Download .nbib Format: NLM
Antihypertensive therapy in older patients with isolated systolic hypertension: the Syst-Eur experience in general practice.

Family practice

Celis H, Yodfat Y, Thijs L, Clement D, Cozic J, De Cort P, Forette F, Gregoire M, Heyrman J, Stibbe G, Van den Haute M, Staessen J, Fagard R, behalf of the Syst-Eur Investigators o.
PMID: 8671117
Fam Pract. 1996;13(2):138-43.

Background and objective. This interim report from the Syst-Eur trial investigated the level of blood pressure control achieved during the double-blind period in patients followed in general practices. Methods. In the Syst-Eur trial elderly patients (60 years or older)...

Cite
Celis H, Yodfat Y, Thijs L, et al. Antihypertensive therapy in older patients with isolated systolic hypertension: the Syst-Eur experience in general practice. Fam Pract. 1996;13(2):138-43
Celis, H., Yodfat, Y., Thijs, L., Clement, D., Cozic, J., De Cort P, Forette, F., Gregoire, M., Heyrman, J., Stibbe, G., Van den Haute M, Staessen, J., Fagard, R., & behalf of the Syst-Eur Investigators o. (1996). Antihypertensive therapy in older patients with isolated systolic hypertension: the Syst-Eur experience in general practice. Family practice, 13(2), 138-43.
Celis, et al. "Antihypertensive therapy in older patients with isolated systolic hypertension: the Syst-Eur experience in general practice." Family practice vol. 13,2 (1996): 138-43.
Celis H, Yodfat Y, Thijs L, Clement D, Cozic J, De Cort P, Forette F, Gregoire M, Heyrman J, Stibbe G, Van den Haute M, Staessen J, Fagard R, behalf of the Syst-Eur Investigators o. Antihypertensive therapy in older patients with isolated systolic hypertension: the Syst-Eur experience in general practice. Fam Pract. 1996;13(2):138-43. PMID: 8671117.
Copy Download .nbib Format: NLM
Valsartan, a new angiotensin II antagonist; blood pressure reduction in essential hypertension compared with an angiotensin converting enzyme inhibitor, enalapril.

Blood pressure monitoring

Mallion JM, Boutelant S, Chabaux P, Baguet JP, Muller M, Meilenbrock S, Heath R, Bodin F.
PMID: 10234113
Blood Press Monit. 1997 Aug;2(4):179-184.

OBJECTIVE: To compare the blood pressure reduction induced by valsartan, a new angiotensin II receptor antagonist, with that induced by enalapril, an angiotensin converting enzyme (ACE) inhibitor in essential hypertension. METHODS: In total 189 adult outpatients with uncomplicated essential...

Cite
Mallion JM, Boutelant S, Chabaux P, et al. Valsartan, a new angiotensin II antagonist; blood pressure reduction in essential hypertension compared with an angiotensin converting enzyme inhibitor, enalapril. Blood Press Monit. 1997;2(4):179-184
Mallion, J. M., Boutelant, S., Chabaux, P., Baguet, J. P., Muller, M., Meilenbrock, S., Heath, R., & Bodin, F. (1997). Valsartan, a new angiotensin II antagonist; blood pressure reduction in essential hypertension compared with an angiotensin converting enzyme inhibitor, enalapril. Blood pressure monitoring, 2(4), 179-184.
Mallion, et al. "Valsartan, a new angiotensin II antagonist; blood pressure reduction in essential hypertension compared with an angiotensin converting enzyme inhibitor, enalapril." Blood pressure monitoring vol. 2,4 (1997): 179-184.
Mallion JM, Boutelant S, Chabaux P, Baguet JP, Muller M, Meilenbrock S, Heath R, Bodin F. Valsartan, a new angiotensin II antagonist; blood pressure reduction in essential hypertension compared with an angiotensin converting enzyme inhibitor, enalapril. Blood Press Monit. 1997 Aug;2(4):179-184. PMID: 10234113.
Copy Download .nbib Format: NLM
Spectral analysis of 24 h blood pressure monitoring in the assessment of trough: peak ratio. A randomized, placebo-controlled, cross-over comparison of ramipril and enalapril.

Blood pressure monitoring

Modesti PA, Toccafondi S, Carnemolla A, Rocchi F, Costoli A, Torri M, Tortoli P.
PMID: 10234131
Blood Press Monit. 1997 Dec;2(6):283-287.

BACKGROUND: The ratio between the magnitude of blood pressure reduction during the steady-state dosage interval (trough) and the maximum blood pressure reduction (peak) is an integrated in-vivo index both of the pharmacokinetic properties and of pharmacodynamic activity of an...

Cite
Modesti PA, Toccafondi S, Carnemolla A, et al. Spectral analysis of 24 h blood pressure monitoring in the assessment of trough: peak ratio. A randomized, placebo-controlled, cross-over comparison of ramipril and enalapril. Blood Press Monit. 1997;2(6):283-287
Modesti, P. A., Toccafondi, S., Carnemolla, A., Rocchi, F., Costoli, A., Torri, M., & Tortoli, P. (1997). Spectral analysis of 24 h blood pressure monitoring in the assessment of trough: peak ratio. A randomized, placebo-controlled, cross-over comparison of ramipril and enalapril. Blood pressure monitoring, 2(6), 283-287.
Modesti, et al. "Spectral analysis of 24 h blood pressure monitoring in the assessment of trough: peak ratio. A randomized, placebo-controlled, cross-over comparison of ramipril and enalapril." Blood pressure monitoring vol. 2,6 (1997): 283-287.
Modesti PA, Toccafondi S, Carnemolla A, Rocchi F, Costoli A, Torri M, Tortoli P. Spectral analysis of 24 h blood pressure monitoring in the assessment of trough: peak ratio. A randomized, placebo-controlled, cross-over comparison of ramipril and enalapril. Blood Press Monit. 1997 Dec;2(6):283-287. PMID: 10234131.
Copy Download .nbib Format: NLM
How well can blood pressure be controlled? Progress report on the Systolic Hypertension in Europe Follow-Up Study (Syst-Eur 2).

Current controlled trials in cardiovascular medicine

Thijs L, Staessen JA, Beleva S, Birkenhäger WH, Bulpitt CJ, Celis H, Fletcher AE, Kermova R, Leonetti G, Laks T, Mantov S, Nachev C, Sarti C, Tuomilehto J, Fagard RH.
PMID: 11806817
Curr Control Trials Cardiovasc Med. 2001 Oct 18;2(6):298-306. doi: 10.1186/cvm-2-6-298.

BACKGROUND: The randomised, double-blind, placebo-controlled Systolic Hypertension in Europe trial (Syst-Eur 1) proved that blood pressure (BP) lowering therapy starting with nitrendipine reduces the risk of cardiovascular complications in elderly patients with isolated systolic hypertension. In an attempt to...

Cite
Thijs L, Staessen JA, Beleva S, et al. How well can blood pressure be controlled? Progress report on the Systolic Hypertension in Europe Follow-Up Study (Syst-Eur 2). Curr Control Trials Cardiovasc Med. 2001;2(6):298-306doi: 10.1186/cvm-2-6-298.
Thijs, L., Staessen, J. A., Beleva, S., Birkenhäger, W. H., Bulpitt, C. J., Celis, H., Fletcher, A. E., Kermova, R., Leonetti, G., Laks, T., Mantov, S., Nachev, C., Sarti, C., Tuomilehto, J., Fagard, R. H. (2001). How well can blood pressure be controlled? Progress report on the Systolic Hypertension in Europe Follow-Up Study (Syst-Eur 2). Current controlled trials in cardiovascular medicine, 2(6), 298-306. https://doi.org/10.1186/cvm-2-6-298
Thijs, Lutgarde, et al. "How well can blood pressure be controlled? Progress report on the Systolic Hypertension in Europe Follow-Up Study (Syst-Eur 2)." Current controlled trials in cardiovascular medicine vol. 2,6 (2001): 298-306. doi: https://doi.org/10.1186/cvm-2-6-298
Thijs L, Staessen JA, Beleva S, Birkenhäger WH, Bulpitt CJ, Celis H, Fletcher AE, Kermova R, Leonetti G, Laks T, Mantov S, Nachev C, Sarti C, Tuomilehto J, Fagard RH. How well can blood pressure be controlled? Progress report on the Systolic Hypertension in Europe Follow-Up Study (Syst-Eur 2). Curr Control Trials Cardiovasc Med. 2001 Oct 18;2(6):298-306. doi: 10.1186/cvm-2-6-298. PMID: 11806817; PMCID: PMC64833.
Copy Download .nbib Format: NLM
Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE).

Current hypertension reports

Ruschitzka FT.
PMID: 12530936
Curr Hypertens Rep. 2003 Feb;5(1):57-8. doi: 10.1007/s11906-003-0011-3.

No abstract available.

Cite
Ruschitzka FT. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Curr Hypertens Rep. 2003;5(1):57-8doi: 10.1007/s11906-003-0011-3.
Ruschitzka, F. T. (2003). Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Current hypertension reports, 5(1), 57-8. https://doi.org/10.1007/s11906-003-0011-3
Ruschitzka, Frank T. "Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE)." Current hypertension reports vol. 5,1 (2003): 57-8. doi: https://doi.org/10.1007/s11906-003-0011-3
Ruschitzka FT. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Curr Hypertens Rep. 2003 Feb;5(1):57-8. doi: 10.1007/s11906-003-0011-3. PMID: 12530936.
Copy Download .nbib Format: NLM
Effect of helicokinins and ACE inhibitors on water balance and development of Heliothis virescens larvae.

Journal of insect physiology

Seinsche A, Dyker H, Lösel P, Backhaus D, Scherkenbeck J.
PMID: 10891570
J Insect Physiol. 2000 Nov 01;46(11):1423-1431. doi: 10.1016/s0022-1910(00)00065-2.

The diuretic activity of the helicokinins I (YFSPWG-amide), II (VRFSPWG-amide) and III (KVKFSAWG-amide) was tested on Heliothis virescens larvae. All three kinins increased fluid secretion in isolated Malpighian tubules in a dose-dependent manner. Injections into the haemolymph caused a...

Cite
Seinsche A, Dyker H, Lösel P, et al. Effect of helicokinins and ACE inhibitors on water balance and development of Heliothis virescens larvae. J Insect Physiol. 2000;46(11):1423-1431doi: 10.1016/s0022-1910(00)00065-2.
Seinsche, A., Dyker, H., Lösel, P., Backhaus, D., & Scherkenbeck, J. (2000). Effect of helicokinins and ACE inhibitors on water balance and development of Heliothis virescens larvae. Journal of insect physiology, 46(11), 1423-1431. https://doi.org/10.1016/s0022-1910(00)00065-2
Seinsche, et al. "Effect of helicokinins and ACE inhibitors on water balance and development of Heliothis virescens larvae." Journal of insect physiology vol. 46,11 (2000): 1423-1431. doi: https://doi.org/10.1016/s0022-1910(00)00065-2
Seinsche A, Dyker H, Lösel P, Backhaus D, Scherkenbeck J. Effect of helicokinins and ACE inhibitors on water balance and development of Heliothis virescens larvae. J Insect Physiol. 2000 Nov 01;46(11):1423-1431. doi: 10.1016/s0022-1910(00)00065-2. PMID: 10891570.
Copy Download .nbib Format: NLM
Heart failure in patients admitted to hospital: mortality is still high.

European journal of internal medicine

Wong PS, Davidsson GK, Timeyin J, Warren A, Watson DJ, Vincent R, Davidson C.
PMID: 12144909
Eur J Intern Med. 2002 Aug;13(5):304-310. doi: 10.1016/s0953-6205(02)00086-9.

BACKGROUND: Two separate cohorts of consecutive patients admitted to hospital with a primary diagnosis of heart failure were studied, the first in 1986 in Rochdale, and the second in 1995 in Brighton. METHODS: We observed the clinical profile, treatment...

Cite
Wong PS, Davidsson GK, Timeyin J, et al. Heart failure in patients admitted to hospital: mortality is still high. Eur J Intern Med. 2002;13(5):304-310doi: 10.1016/s0953-6205(02)00086-9.
Wong, P. S., Davidsson, G. K., Timeyin, J., Warren, A., Watson, D. J., Vincent, R., & Davidson, C. (2002). Heart failure in patients admitted to hospital: mortality is still high. European journal of internal medicine, 13(5), 304-310. https://doi.org/10.1016/s0953-6205(02)00086-9
Wong, P S., et al. "Heart failure in patients admitted to hospital: mortality is still high." European journal of internal medicine vol. 13,5 (2002): 304-310. doi: https://doi.org/10.1016/s0953-6205(02)00086-9
Wong PS, Davidsson GK, Timeyin J, Warren A, Watson DJ, Vincent R, Davidson C. Heart failure in patients admitted to hospital: mortality is still high. Eur J Intern Med. 2002 Aug;13(5):304-310. doi: 10.1016/s0953-6205(02)00086-9. PMID: 12144909.
Copy Download .nbib Format: NLM
Endothelin-receptor antagonists: current and future perspectives.

Drug discovery today

Ray A, Hegde LG, Chugh A, Gupta JB.
PMID: 11018597
Drug Discov Today. 2000 Oct 01;5(10):455-464. doi: 10.1016/s1359-6446(00)01557-9.

Despite much effort over recent years to design and develop endothelin-receptor antagonists, these compounds are far from becoming new drug entities. This article will review preclinical data on select endothelin-receptor antagonists as well as clinical data on bosentan, the...

Cite
Ray A, Hegde LG, Chugh A, et al. Endothelin-receptor antagonists: current and future perspectives. Drug Discov Today. 2000;5(10):455-464doi: 10.1016/s1359-6446(00)01557-9.
Ray, A., Hegde, L. G., Chugh, A., & Gupta, J. B. (2000). Endothelin-receptor antagonists: current and future perspectives. Drug discovery today, 5(10), 455-464. https://doi.org/10.1016/s1359-6446(00)01557-9
Ray, et al. "Endothelin-receptor antagonists: current and future perspectives." Drug discovery today vol. 5,10 (2000): 455-464. doi: https://doi.org/10.1016/s1359-6446(00)01557-9
Ray A, Hegde LG, Chugh A, Gupta JB. Endothelin-receptor antagonists: current and future perspectives. Drug Discov Today. 2000 Oct 01;5(10):455-464. doi: 10.1016/s1359-6446(00)01557-9. PMID: 11018597.
Copy Download .nbib Format: NLM
A Comparison of the Cough Profile of Fosinopril and Enalapril in Hypertensive Patients with a History of ACE Inhibitor-Associated Cough.

American journal of therapeutics

David D, Jallad N, Germino FW, Willett MS, de Silva J, Weidner SM, Mills DJ.
PMID: 11854791
Am J Ther. 1995 Oct;2(10):806-813. doi: 10.1097/00045391-199510000-00013.

OBJECTIVE: Cough frequency and severity with fosinopril and enalapril were assessed in hypertensive patients with previous angiotensin-converting enzyme inhibitor (ACEI)-associated cough. DESIGN: Prospective, multicenter, randomized, 8-week double-blind treatment. PATIENTS: One hundred seventy-nine patients (mild-to-moderate hypertension, nonsmokers, mean age 58...

Cite
David D, Jallad N, Germino FW, et al. A Comparison of the Cough Profile of Fosinopril and Enalapril in Hypertensive Patients with a History of ACE Inhibitor-Associated Cough. Am J Ther. 1995;2(10):806-813doi: 10.1097/00045391-199510000-00013.
David, D., Jallad, N., Germino, F. W., Willett, M. S., de Silva, J., Weidner, S. M., & Mills, D. J. (1995). A Comparison of the Cough Profile of Fosinopril and Enalapril in Hypertensive Patients with a History of ACE Inhibitor-Associated Cough. American journal of therapeutics, 2(10), 806-813. https://doi.org/10.1097/00045391-199510000-00013
David, Daniel, et al. "A Comparison of the Cough Profile of Fosinopril and Enalapril in Hypertensive Patients with a History of ACE Inhibitor-Associated Cough." American journal of therapeutics vol. 2,10 (1995): 806-813. doi: https://doi.org/10.1097/00045391-199510000-00013
David D, Jallad N, Germino FW, Willett MS, de Silva J, Weidner SM, Mills DJ. A Comparison of the Cough Profile of Fosinopril and Enalapril in Hypertensive Patients with a History of ACE Inhibitor-Associated Cough. Am J Ther. 1995 Oct;2(10):806-813. doi: 10.1097/00045391-199510000-00013. PMID: 11854791.
Copy Download .nbib Format: NLM
An optimized fluoroenzymatic assay for the determination of angiotensin converting enzyme inhibitors in biological fluids.

Journal of pharmaceutical and biomedical analysis

Shepley K, Rocci ML, Patrick H, Mojaverian P.
PMID: 16867414
J Pharm Biomed Anal. 1988;6(3):241-51. doi: 10.1016/0731-7085(88)80050-5.

An easy, analytically sound fluoroenzymatic assay for angiotensin converting enzyme (ACE) inhibitors is described. Drug samples and standards are extracted with methanol and evaporated to dryness. Drug residues are then incubated with the substrate N-benzyloxycarbonyl-phenyllanyl-l-histidyl-leucine and human plasma ACE...

Cite
Shepley K, Rocci ML, Patrick H, et al. An optimized fluoroenzymatic assay for the determination of angiotensin converting enzyme inhibitors in biological fluids. J Pharm Biomed Anal. 1988;6(3):241-51doi: 10.1016/0731-7085(88)80050-5.
Shepley, K., Rocci, M. L., Patrick, H., & Mojaverian, P. (1988). An optimized fluoroenzymatic assay for the determination of angiotensin converting enzyme inhibitors in biological fluids. Journal of pharmaceutical and biomedical analysis, 6(3), 241-51. https://doi.org/10.1016/0731-7085(88)80050-5
Shepley, K, et al. "An optimized fluoroenzymatic assay for the determination of angiotensin converting enzyme inhibitors in biological fluids." Journal of pharmaceutical and biomedical analysis vol. 6,3 (1988): 241-51. doi: https://doi.org/10.1016/0731-7085(88)80050-5
Shepley K, Rocci ML, Patrick H, Mojaverian P. An optimized fluoroenzymatic assay for the determination of angiotensin converting enzyme inhibitors in biological fluids. J Pharm Biomed Anal. 1988;6(3):241-51. doi: 10.1016/0731-7085(88)80050-5. PMID: 16867414.
Copy Download .nbib Format: NLM
Enalapril suppresses ventricular remodeling after acute myocardial infarction more effectively than losartan.

Evidence-based cardiovascular medicine

Eifer Møller J, Singh D.
PMID: 16530673
Evid Based Cardiovasc Med. 2006 Mar;10(1):32-4. doi: 10.1016/j.ebcm.2006.01.031. Epub 2006 Mar 06.

No abstract available.

Cite
Eifer Møller J, Singh D. Enalapril suppresses ventricular remodeling after acute myocardial infarction more effectively than losartan. Evid Based Cardiovasc Med. 2006;10(1):32-4doi: 10.1016/j.ebcm.2006.01.031.
Eifer Møller, J., & Singh, D. (2006). Enalapril suppresses ventricular remodeling after acute myocardial infarction more effectively than losartan. Evidence-based cardiovascular medicine, 10(1), 32-4. https://doi.org/10.1016/j.ebcm.2006.01.031
Eifer Møller, Jacob, and Singh, Debbie. "Enalapril suppresses ventricular remodeling after acute myocardial infarction more effectively than losartan." Evidence-based cardiovascular medicine vol. 10,1 (2006): 32-4. doi: https://doi.org/10.1016/j.ebcm.2006.01.031
Eifer Møller J, Singh D. Enalapril suppresses ventricular remodeling after acute myocardial infarction more effectively than losartan. Evid Based Cardiovasc Med. 2006 Mar;10(1):32-4. doi: 10.1016/j.ebcm.2006.01.031. Epub 2006 Mar 06. PMID: 16530673.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 451 entries